Onkologie. 2007:1(2):73-78

Bioptic diagnosis of gastrointestinal stromal tumors

Lukáš Plank
Ústav patologickej anatómie JLF UK a MFN, Martin

Gastrointestinal stromal tumors (GIST-s) are the most common mesenchymal tumors of the gastrointestinal tract. They usually show immunohistochemical positivity of CD117 antigen and mutations of the tyrosin kinase receptor – c-KIT or PDGFRA gene. The objective of the paper is to summarize current informations on importance of their biopsy diagnosis, especially in relation to the determination of the GIST´s histologic type, its phenotype and results of the mutational analyses. The importance of all these parameters for the diagnosis and differential diagnosis of GIST´s, its prognosis and therapy is discussed.

Keywords: gastrointestinal stromal tumor, GIST, biopsy diagnosis, prognostic and predictive parameters, tyrosin kinase receptor mutations, KIT, PDGFRA

Published: October 23, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Plank L. Bioptic diagnosis of gastrointestinal stromal tumors. Onkologie. 2007;1(2):73-78.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Miettinen M, Lasota J. Gastrointestinal stromal tumors. Review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch. Pathol. Lab. Med., 2006, 130: 1466-1478. Go to original source...
    2. Daum O, Vaněček T, Šíma R. Michal M. Gastrointestinální stromální tumor: současný pohled. Klin. Onkol., 2006, 19 (4), s. 203-211.
    3. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal tumors. J. Clin. Oncol. 22, 18, 2004, s. 3813-3825. Go to original source... Go to PubMed...
    4. Fletcher CDM, Berman JJ, Corless Chr, et al. Diagnosis of gastrointestinal stromal tumors - a consensus approach. Hum. Pathol. 33, 5, 2002, s. 459-465. Go to original source... Go to PubMed...
    5. Blay J-Y, Bonvalot S, Casali P, et al. Consensus meeting for the managment of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20 - 21 March 2004, under the auspices of ESMO. Annals Oncol. 16, 4, 2005, s. 566-578. Go to original source... Go to PubMed...
    6. Strickland L, Letson D, Muro-Cacho. Gastrointestinal stromal tumors. Cancer Control 2001, 8 (3): 252-261. Go to original source... Go to PubMed...
    7. Pauwel P, Debiec-Rychter M, Stul M, De Wever I, Van Oosterom AT, Sciot R. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall. Histopathology 2005, 47 (1): 41-47. Go to original source... Go to PubMed...
    8. Rossi G, Sartori G, Valli R, Bertolini F, Bigiani N, Schirosi L, Cavazza A, Luppi G. The value of c-kit mutational analysis in a cytokeratin positive gastrointestinal stromal tumour. J. Clin. Pathol. 2205, 58 (9): 991-993. Go to original source... Go to PubMed...
    9. Plank L. Úloha a možnosti patológa v onkológii. Onkológia (Bratisl.), 2006, 1 (1): 33-38.
    10. Plank L. Celoštátny program bioptickej diagnostiky gastrointestinálnych stromálnych tumorov v Slovenskej republike. Gastroenterológia 2007, in press.
    11. Fletcher CDM. An updated based on the new WHO classification. In: Update in Pathology 2005, Zborník 20. kongresu Európskej spoločnosti patológov, Paríž, 3.-8. september 2005, s. 434-437.
    12. Franquemont DW. Differentiation and risk assessment of gastrointestinal stromal tumors. Am. J. Clin. Pathol., 1995, 103: 41-47. Go to original source... Go to PubMed...
    13. Reith JD, Goldblum JR, Lyles RH, Weiss Sh. Extragastrointestinal (soft tissue) stromal tumors: An analysis of 48 cases with emphasis on histologic predictors of outcome. Mod. Pathol. 2000, 13 (5): 577-585. Go to original source... Go to PubMed...
    14. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann. Surg., 2000, 213: 51-58. Go to original source... Go to PubMed...
    15. Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG, DeSantis D, Brennan MF, Singer S, DeMatteo RP, Antonescu CR. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Clin. Cancer Res., 2007, 13 (1): 170-181. Go to original source... Go to PubMed...
    16. Heinrich MC, Corless ChrL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher ChrDM, Sandau K, McDougall K, Ou W, Chen Ch-J, Fletcher JA. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J. Clin. Oncol., 2006, 24 (29): 4764-4774. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.